TUMOUR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS (VEGFR) POLYMORPHISMS AND CLINICAL OUTCOME IN ADVANCED RENAL CELL CARCINOMA PATIENTS RECEIVING FIRST LINE SUNITINIB

被引：0
|
作者：
Bianconi, M. [1 ]
Scartozzi, M. [1 ]
Faloppi, L. [1 ]
Loretelli, C. [1 ]
Burattini, L. [1 ]
Bittoni, A. [1 ]
Del Prete, M. [1 ]
Giampieri, R. [1 ]
Montironi, R. [2 ]
Cascinu, S. [1 ]
机构：
[1] Univ Politecn Marche, AOU Osped Riuniti Ancona, Clin Oncol Med, Ancona, Italy
[2] Univ Politecn Marche, Inst Pathol Anat, Ancona, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：274 / 274
页数：1
相关论文
共 50 条
  • [1] The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib
    Bianconi, Maristella
    Scartozzi, Mario
    Faloppi, Luca
    Giampieri, Riccardo
    Maccaroni, Elena
    Bittoni, Alessandro
    Del Prete, Michela
    Loretelli, Cristian
    Belvederesi, Laura
    Conti, Alessandro
    Burattini, Luciano
    Minardi, Daniele
    Silva, Rosa Rita
    Montironi, Rodolfo
    Cascinu, Stefano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib.
    Bianconi, Maristella
    Scartozzi, Mario
    Faloppi, Luca
    Giampieri, Riccardo
    Maccaroni, Elena
    Bittoni, Alessandro
    Del Prete, Michela
    Loretelli, Cristian
    Belvederesi, Laura
    Conti, Alessandro
    Minardi, Daniele
    Burattini, Luciano
    Montironi, Rodolfo
    Cascinu, Stefano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [3] THE ROLE OF TUMOUR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS (VEGFR) POLYMORPHISMS IN THE PREDICTION OF CLINICAL OUTCOME FOR ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB
    Faloppi, L.
    Scartozzi, M.
    Baroni, G. Svegliati
    Loretelli, C.
    De Minicis, S.
    Mandolesi, A.
    Bianconi, M.
    Bearzi, I.
    Benedetti, A.
    Cascinu, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 243 - 243
  • [4] The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib
    Faloppi, Luca
    Scartozzi, Mario
    De Minicis, Samulele
    Baroni, Gianluca Svegliati
    Bianconi, Maristella
    Giampieri, Riccardo
    Maccaroni, Elena
    Bittoni, Alessandro
    Del Prete, Michela
    Mandolesi, Alessandra
    Loretelli, Cristian
    Belvederesi, Laura
    Biagetti, Simona
    Bearzi, Italo
    Benedetti, Antonio
    Cascinu, Stefano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib
    Faloppi, Luca
    Scartozzi, Mario
    Loretelli, Cristian
    Bianconi, Maristella
    Giampieri, Riccardo
    Bittoni, Alessandro
    Del Prete, Michela
    Mandolesi, Alessandra
    Bearzi, Italo
    Cascinu, Stefano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] Expression of vascular endothelial growth factor (VEGF) and activated vascular endothelial growth factor receptors (VEGFR) in renal cell carcinoma
    Ha, Byeong Keun
    Park, Moonja Chung
    [J]. MODERN PATHOLOGY, 2006, 19 : 82 - 82
  • [7] Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients
    Zhong, Weifeng
    Wang, Xiaohong
    Pan, Bin
    Su, Zexuan
    [J]. TUMOR BIOLOGY, 2014, 35 (10) : 9839 - 9845
  • [8] Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients
    Ma, Nan
    Li, Li-Wei
    Cheng, Jing-Liang
    [J]. ONCOLOGY LETTERS, 2015, 9 (02) : 651 - 656
  • [9] Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms
    Berardi, Rossana
    Torniai, Mariangela
    Partelli, Stefano
    Rubini, Corrado
    Pagliaretta, Silvia
    Savini, Agnese
    Polenta, Vanessa
    Santoni, Matteo
    Giampieri, Riccardo
    Onorati, Sofia
    Barucca, Federica
    Murrone, Alberto
    Bianchi, Francesca
    Falconi, Massimo
    [J]. PLOS ONE, 2018, 13 (05):
  • [10] VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    Scartozzi, M.
    Bianconi, M.
    Faloppi, L.
    Loretelli, C.
    Bittoni, A.
    Del Prete, M.
    Giampieri, R.
    Maccaroni, E.
    Nicoletti, S.
    Burattini, L.
    Minardi, D.
    Muzzonigro, G.
    Montironi, R.
    Cascinu, S.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1126 - 1132
12345